congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
T-DXd
ESMO Asia 2023 | December 1-3, 2023
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Oral
T-DXd
JSMO 2024 | February 22-24, 2024
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Poster
Dato-DXd, T-DXd, Valemetostat
ASCO 2024 | May 31 - June 4, 2024
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Poster
T-DXd
ESMO 2023 | October 20-24, 2023
Characteristics, treatment patterns, and outcomes of patients with advanced/metastatic gastric cancer or gastro-esophageal junction adenocarcinoma previously treated with anti-HER2 therapy in an English national registry
Oral
T-DXd
ESMO 2023 | October 20-24, 2023
Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors harboring specific activating HER2 mutations: Primary results from the international phase 2 DESTINY-PanTumor01 study
Poster
Dato-DXd
AACR 2024 | April 5-10, 2024
Evaluating the combination of datopotamab deruxtecan (Dato-DXd) with saruparib (AZD5305), a highly potent, PARP1-selective inhibitor, in preclinical models
Poster
HER3-DXd
ASCO 2024 | May 31 - June 4, 2024
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors
Poster
T-DXd
ISPOR 2024 | May 5-8, 2024
Perceptions, experiences, and behaviors of patients and their caregivers with gastric and gastroesophageal junction cancer treated with or without trastuzumab deruxtecan in the United States
Poster
T-DXd
ASCO GI 2024 | January 18-20, 2024
Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients with HER2+ and HER2-low gastric cancer (DESTINY-Gastric03)
Poster
T-DXd
ASCO GI 2024 | January 18-20, 2024
Real-world experience with trastuzumab deruxtecan among patients with gastric cancer: 4 month-interim analysis of an all-patient post-marketing surveillance study in Japan
Páginas:
1 2